Compounded Semaglutide vs Tesofensine
A side-by-side research comparison of Compounded Semaglutide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Compounded Semaglutide | Tesofensine |
|---|---|---|
| Full name | Compounded Semaglutide (503B Pharmacy) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | Phase 3 Clinical Trial |
| Mechanism | Identical to branded semaglutide - a GLP-1 receptor agonist with a fatty acid chain for albumin binding, providing extended half-life. Reduces appetite, slows gastric emptying, and improves insulin sensitivity. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 4113.58 Da | 329.4 Da |
| Half-life | ~7 days | 8-10 days |
| Bioavailability | ~89% subcutaneous | High (oral ~93%) |
| Typical dose | 0.25-2.4 mg | 0.25-0.5 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous injection | Oral |
Compounded Semaglutide reported benefits
- Significant weight loss (15-20%)
- Appetite suppression
- Improved glycemic control
- Cardiovascular benefits
- Reduced food noise
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.